Zhenoluten
A-15, ovary peptide bioregulator
Zhenoluten is an ovary-derived peptide complex, listed as A-15. The claim attached to it is the most biologically ambitious in this whole catalog, and almost nobody selling it seems to realize that: ovarian reserve is fixed and declines on a schedule, so a product that genuinely supported it would be claiming something extraordinary. Extraordinary claims are not disqualifying. They do raise the bar on evidence, and here the evidence count is 0.
Zhenoluten quick facts
| Reported research dose | 40-160mg daily (1-2 capsules, 1-2x daily with food · 40mg/capsule) |
| Route | Oral |
| Frequency | 1-2x Daily · Daily during a course |
| Half-life | Not characterized |
| Forms | Oral |
| Evidence level | Theoretical — Khavinson-school work, largely Russian-language and rarely replicated outside it |
The Khavinson literature behind this is decades deep, almost entirely Russian-language, and rarely replicated by any independent group — small single-arm series rather than controlled trials. Absence of replication is not evidence it fails; it is an absence of the evidence that would settle it either way. Dose and course length follow the manufacturer's convention, not a trial. The female reproductive peptide of the set, the counterpart to Testoluten. Course pattern: roughly 10 days on, then off, once or twice a year. To know whether it did anything, AMH, FSH and estradiol, interpreted against where you are in the cycle. Run it as an experiment you measure, not a protocol you trust.
What Zhenoluten actually is — and why that changes the mechanism
Zhenoluten is an ovary-derived peptide complex in capsules, listed as A-15. The mechanism claim is the class one, and applying it to the ovary produces the most ambitious proposition in this entire catalog — which almost nobody selling it appears to notice.
Why the ovarian version of this claim is different in kind. Most targets in this cohort are tissues that renew: gastric mucosa turns over in days, muscle and marrow continuously, liver on demand. A transcriptional nudge toward a younger pattern is at least conceivable in a renewing tissue. The ovary, in the standard model, does not renew — the follicle pool is established before birth and declines monotonically thereafter, which is why menopause happens on a schedule and why the decline is measurable. A product that genuinely supported ovarian reserve would be claiming something about follicle biology that would matter far beyond this catalog.
That is a reason for a high evidential bar, not a reason to dismiss. The correct response to an extraordinary claim is to identify the cheap measurement that would test it, and here it exists and is routine. Anti-Mullerian hormone is produced by granulosa cells of small growing follicles and reports the size of that pool, running about 1.0-4.0 ng/mL in the late twenties to early thirties and falling with age, with under 1.0 suggesting diminished reserve. It costs a fraction of a course. It has never been measured before and after this product, in 0 published studies.
And what the label commits to, quantified. A 2-residue peptide has 400 possible identities, a 4-residue one 160,000; 'peptide complex' excludes none. The 2021 gene-expression review that carries the class mechanism is indexed by sequence — 98 genes for AEDG, 36 for Lys-Glu — and has 0 ovarian entries. The transcription story on this capsule is inherited from molecules nobody has demonstrated are in it.
What the primary literature on Zhenoluten actually says
Peptide Regulation of Gene Expression: A Systematic Review
Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR · Molecules 2021;26(22):7053 · PMID 34834147
The 2021 gene-expression review, the source of the class mechanism. Indexed by peptide sequence, with 98 genes credited to AEDG and 36 to Lys-Glu, and no entry for an ovarian preparation of any kind. The transcription claim on this product's label is a claim about other molecules.
Systematic search for structural motifs of peptide binding to double-stranded DNA
Kolchina N, Khavinson V, Linkova N, Yakimov A, Baitin D, Afanasyeva A, Petukhov M · Nucleic Acids Research 2019;47(20):10553–10563 · PMID 31598715
The 2019 docking screen, 108,800 peptide-DNA complexes, binder threshold near -32. Defined sequences only. Nothing derived from ovarian tissue has been screened, because nothing derived from ovarian tissue has been identified.
The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis
Alsulaimani RA, Quinn TJ (independent — not the Khavinson group) · Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
The 2021 independent review — 24 randomized trials, 2,245 participants, certainty of evidence low to very low. Cognitive endpoints. It is on this page as calibration for what an outside grader concludes about this class, not as evidence about ovaries.
What is not here. Nothing is indexed under the trade name Zhenoluten. No AMH, FSH or cycle endpoint has been published for any ovary-derived peptide preparation in this family. Searched through Europe PMC, PubMed and Google Scholar on 2 September 2026. Naming the gap is more useful than filling it with a paragraph of hedging.
Why the Zhenoluten evidence is weak — and what it still showed
Almost every human result in this class comes from one school — Vladimir Khavinson's institute in St Petersburg and the groups around it. That means single-center data, collected by the people who developed the compound, rarely blinded, never pre-registered, and reported across enough endpoints that something was always going to move. Read anything below against that.
Specific to Zhenoluten. The problem specific to Zhenoluten is that its central claim is checkable with one test that costs very little and is already ordered routinely in fertility clinics. Anti-Mullerian hormone runs around 1.0-4.0 ng/mL in the late twenties to early thirties and falls with age, with values under 1.0 suggesting diminished reserve. If an ovarian preparation did anything to reserve, AMH is where it would appear. It has never been measured before and after a course of this or any similar product, in 0 published studies.
The count: 0. Nothing is indexed under the trade name Zhenoluten, and 0 AMH, FSH or cycle endpoints have been published for any ovary-derived peptide preparation in this family. Searched through Europe PMC, PubMed and Google Scholar on 2 September 2026.
What that means against a claim of this size. The standard evidential rule is that the strength of evidence required scales with how surprising the claim is. A product asserting an effect on a follicle pool that the field regards as non-renewable is at the far end of that scale, and it arrives with less evidence than any compound on this site: not a small trial, not an animal study, not a cell-culture result, not a case series. Zero of each, over the 5 years since the 2021 review of this class and every year before it.
Held against the class's own record. The 266-subject elderly series that vendor pages cite used thymus and pineal preparations by injection, over 6-8 years, with no gynecological endpoint of any kind. The 2021 independent systematic review pooled 24 randomized trials over 2,245 participants on cognitive outcomes and graded risk of bias moderate to high with certainty of evidence low to very low. Neither is about ovaries, and both are routinely cited as though the class record transfers. It does not.
What is actually measured, and what is not. Measured: nothing. Not measured, and this is the list that matters: AMH, which runs about 1.0-4.0 ng/mL in the late twenties to early thirties and under 1.0 in diminished reserve; FSH, which moves the opposite way; mid-luteal progesterone, where above 3 ng/mL confirms ovulation. Every one of those is ordered routinely in fertility clinics, and 0 of them have ever been reported before and after a course of this product.
Not proven is not the same as disproven. Everything above says the evidence is weak. None of it says the compound does nothing. There is no adequately powered trial that ran and came back null, because outside Russia there is essentially no trial at all — this class is unfunded, not failed. A reader who leaves thinking “disproven” has learned something false, and so has one who leaves thinking “proven”.
Zhenoluten pharmacokinetics — how much of it actually gets in
'Not characterized' is the honest field value. A mixture has one clearance curve per component, so a single half-life could not be correct, and 0 measurements exist for this preparation in any species.
What can be reasoned. A short peptide reaching plasma meets serum aminopeptidases and is cut from its termini within minutes. That does not by itself defeat a transcriptional claim, since the signal can outlast the molecule, but it does mean serum concentration is the wrong thing to chase and the interesting quantity for a capsule is absorption. The only named route for intact peptide across the gut wall is PEPT1 on the brush-border membrane of the small intestine, whose substrate range the class's own 2022 review gives as di- and tripeptides — 2 and 3 residues — and anything crossing then meets hepatic first-pass extraction.
Now do the arithmetic the blank was hiding. Compare the oral products in this class against the injectable ones and the oral form carries roughly 29x more material per day, and on the order of 571x more across a full course. Take an injection as fully bioavailable — 100% by definition, no gut wall, no hepatic first-pass — and the implication is direct: for the oral route to deliver comparable systemic exposure, on the order of 0.2% of what is swallowed would have to arrive in the circulation intact. Whether a peptide mixture can manage that has never been measured — not for this product and not for any product in this family. Stating the bound is honest. Claiming the fraction would not be.
One more constraint that is specific to this target. Even a peptide that reached the circulation has to reach a follicle, and follicles are avascular structures fed by diffusion across the basement membrane from the theca vasculature. That is a second barrier after the gut, it is real physiology rather than rhetoric, and 0 papers in this class address it.
What would have to be true for Zhenoluten to work
The chain, and step 5 is the one that would make news. (1) The capsule would have to contain active peptides — 0 assays published. (2) Some fraction would have to cross the gut wall intact — the named route carries 2- and 3-residue peptides; this is a complex. (3) It would have to reach granulosa or theca cells across the follicular basement membrane — never measured. (4) It would have to change transcription there — never observed in ovarian tissue for anything in this class. (5) The follicle pool would have to respond — which would be a finding about ovarian biology, not just about this product.
Why the predictions below are worth running even so. Two of them move in opposite directions if reserve genuinely changed — AMH up, FSH down — which makes a coincidence much harder to mistake for an effect than a single number moving on its own. And one of them, a mid-luteal progesterone above 3 ng/mL drawn around day 21 of a 28 day cycle, is a hard binary: the cycle either ovulated or it did not.
- Prediction 1 — Anti-Müllerian Hormone (AMH). would have to rise, and a rise would be the extraordinary result, 3-6 months, since AMH reflects the antral follicle pool rather than a single cycle. This is the prediction that defines the page. AMH reports the size of the growing follicle pool, and in the standard model that pool is not replenished. A confirmed rise would be a genuinely significant finding about ovarian biology, not just about this product — which is exactly why the absence of anyone having looked is so striking.
- Prediction 2 — LH & FSH. FSH should fall if reserve improved; postmenopausal values run above 25 mIU/mL and follicular FSH 3-10, 3-6 months. FSH rises as reserve falls, because less inhibin feedback reaches the pituitary. It is the older, cheaper proxy for the same thing AMH measures, it moves in the opposite direction, and having both makes a single odd result much harder to over-read.
- Prediction 3 — progesterone. a mid-luteal value above 3 ng/mL confirms ovulation; above 10 ng/mL is robust, mid-luteal phase, across 1-2 cycles. This is the hardest, cheapest, most binary endpoint available on this page. In someone with irregular cycles, an anovulatory cycle becoming ovulatory is a real event with a number attached. If a product claims ovarian support and this does not change over two cycles, it has been given a fair test and failed it.
- Prediction 4 — Estradiol, Sensitive (LC/MS-MS). should be read against cycle phase, not as a single number, with the progesterone draw. Estradiol runs 20-150 pg/mL follicular, peaks 150-750 mid-cycle and sits under 30 postmenopausal, so a value means nothing without knowing the day. This entry exists to stop the most common misreading of a before-and-after in a cycling woman.
Run these before and after, not after alone. A single post-course number tells you what your body is doing, not what Zhenoluten did to it — and that difference is the entire point of testing.
Zhenoluten versus the alternatives
Zhenoluten versus Endoluten. Both are marketed into the same conversation about female aging and both carry 0 indexed studies under their trade names. The pineal product at least has an adjacent human literature to point at, on Epithalamin, which is a different preparation but a real one; the ovarian product has nothing adjacent at all. Neither difference amounts to evidence.
And against what actually has trial evidence in the menopausal transition, which is the paragraph that matters. Menopausal hormone therapy has been studied in randomized trials enrolling tens of thousands of women, with published effects on vasomotor symptoms, bone density and genitourinary symptoms, and a risk profile that varies with age at initiation, formulation and route — a genuinely complicated evidence base that a clinician can walk through with you. Where fertility rather than symptoms is the question, reproductive endocrinology has an entire measurement apparatus, starting with the AMH and FSH pair this page recommends. Both of those conversations are age-sensitive, and AMH below 1.0 ng/mL is the number that makes that concrete. Spending 6 months on a capsule with 0 published results is a real cost in the one situation where time is the scarce resource.
What you are actually buying when you buy Zhenoluten
An ovarian extract cannot be identity-tested. A certificate covers sterility, endotoxin, total protein and named contaminants; it cannot confirm contents, because a preparation defined by its process has no formula and no mass to check. 2 vials with clean certificates can hold different mixtures.
The question worth asking a vendor here. Not for a certificate — ask what the source tissue and species are, and whether a mass-spectrometry profile of the capsule contents exists in any form. A profile would not establish identity, because there is nothing to match against, but it would be the first published compositional fact about an ovarian bioregulator and 0 vendors in this market offer one. A vendor who cannot answer either question is selling a description rather than a product.
An ovarian extract cannot be identity-tested; a certificate can cover sterility, endotoxin, total protein and named contaminants and nothing else. The specific thing to know here is that this product is sold into a population with a deadline — fertility decisions are age-sensitive — and an unverifiable capsule is a poor reason to spend months.
Where to get Zhenoluten
Buy Zhenoluten at BioLongevity Supplements →The evidence for Zhenoluten
Graded by what exists behind each claim.
Human clinical evidence
- No randomized human trials — a research compound with no commercial route to funding one, so the correlative and theoretical tiers are the evidence base rather than a consolation prize.
📊 Correlative data
- The Khavinson group reported improvements in organ-specific markers across a long series of studies from the 1980s onward. These are overwhelmingly small, single-arm, and published in Russian-language journals; independent replication outside that school is close to absent.
🧪 How the mechanism reads
- The proposal is tissue specificity: a short peptide fraction taken from one organ acts preferentially on that same organ, binding regulatory DNA sequences and shifting protein synthesis toward a younger pattern. It is a coherent mechanism and it is why these are dosed as short courses rather than continuously.
- Oral delivery is the open question, not the mechanism. Peptides are poorly absorbed intact from the gut, which is why the oral capsules run 10-20x the injectable milligram dose. Whether enough survives to reach the target tissue has not been shown in a way anyone outside the manufacturer can check.
What that tier rests on here. The tier above is class inference, and it is carrying the most ambitious claim in the catalog. Nothing is indexed under the trade name Zhenoluten and no AMH, FSH or cycle endpoint has been published for any ovary-derived preparation in this family.
Why an empty tier is not a verdict →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
Cell, rodent, human — and where it stops
The only indexed work in this school that touches ovarian function used the pineal extract, in 1980. Gadzhieva 1980 reports the effect of epithalamin on hypophyseal and ovarian gonadotropic function. Read the title carefully: the route to the ovary in that paper runs through the pituitary. The mechanism on offer is central and indirect, not a direct action on ovarian tissue.
The one female clinical report is also about a different product and a different organ. Komarov 1995 describes the use of epithalamin in climacteric myocardiopathy — menopausal women, a cardiac complaint, a pineal preparation, published in Russian in 1995. It is the nearest thing to female-specific human data anywhere in this family, and it is not about an ovary.
Ovarian tissue is absent from the group's own extract survey. Ryzhak 2015 tested cortex, pineal, liver, prostate, thymus, heart and cartilage in organotypic culture. Ovary is not among them, so this tissue has no explant result to point at either. A PubTator3 search on 6 September 2026 under the trade name, and for peptide bioregulators against ovarian and menopausal endpoints, returned nothing.
Where it stops. Khavinson 2012 and Khavinson 2021 carry the class doctrine and reach no ovary. There is no AMH value, no FSH value, no antral follicle count, no cycle data and no menopausal symptom score for this product in any published record.
What nobody has tested yet
Anti-Mullerian hormone is the measurement this product implies and nobody has taken. AMH reflects the remaining follicle pool, is stable across the cycle, and is a single blood test. If an ovarian peptide preparation did anything to ovarian reserve, AMH is where it would appear. Zero published values exist for this class.
FSH and estradiol, drawn on the right day, cost very little. Early-follicular FSH with estradiol is the standard pair for assessing ovarian function, and a menopause-specific symptom scale adds a validated subjective endpoint for free. A product marketed to women around the menopausal transition with none of these reported has not engaged with its own claim.
Extrapolation, labeled as such. If the 1980 result is the real mechanism, then anything this class does to female reproductive function is mediated by gonadotropins from the pituitary rather than by the ovary — which predicts that a pineal preparation should work at least as well as an ovarian one, and that the tissue on the label is decorative. That is a straightforward two-arm comparison, it would test the central doctrine of this entire category in the one system where an old result already points against it, and it has never been run.
Sources read for this page
- Gadzhieva TS. Effect of epithalamin on hypophyseal and ovarian gonadotropic function. Akusherstvo i Ginekologiia (Moskva) 1980 [Russian] · PMID 7192059
- Komarov FI. Use of epithalamin in climacteric myocardiopathy. Klinicheskaia Meditsina (Moskva) 1995 [Russian] · PMID 7474816
- Ryzhak AP, Chalisova NI, Lin'kova NS, Khalimov RI, Ryzhak GA, Zhekalov AN. [Polypeptides influence on tissue cell cultures regeneration of various age rats]. Advances in Gerontology 2015;28(1):97-103 [Russian] · PMID 26390619
- Khavinson VKh. Peptides tissue-specifically stimulate cell differentiation during their aging. Bulletin of Experimental Biology and Medicine 2012 · PMID 22808515
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
Zhenoluten — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Zhenoluten — safety specifics for this compound
Specific to Zhenoluten: 0 adverse-event tables have been published for any ovary-derived preparation in this family, so nothing here is a report of harm. The named risks are two and both are about timing. First, fertility questions are age-sensitive in a way most health questions are not: reserve declines on a schedule, AMH under 1.0 ng/mL suggests diminished reserve, and 6 months spent on an unstudied capsule is 6 months not spent on an assessment that could still change a decision. Second, abnormal bleeding, a new pelvic symptom or postmenopausal bleeding are findings that need a cause rather than a supplement, and postmenopausal estradiol should sit under 30 pg/mL, so a value that does not is worth explaining. The class doctrine above already excludes pregnancy and active malignancy on mechanistic grounds; for an ovary-directed product in particular, any estrogen-sensitive condition is a conversation to have before rather than after.
Zhenoluten — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Zhenoluten moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
Zhenoluten — what interferes with this one specifically
The interference here is the menstrual cycle itself, and it wrecks more self-experiments than any drug does. Estradiol runs 20-150 pg/mL in the follicular phase, peaks at 150-750 mid-cycle and sits at 30-450 in the luteal phase, so a before-and-after taken on 2 arbitrary days can move several-fold with nothing having changed. Progesterone is worse: under 1 ng/mL follicular against above 3 ng/mL mid-luteal, which is a categorical difference driven purely by timing. Any comparison has to be phase-matched or it is noise. Second, and common: hormonal contraception suppresses the axis and lowers AMH somewhat, so results on it do not describe your own ovarian function. Third: AMH above 4-5 ng/mL is common in polycystic ovary syndrome, which means a high value is not automatically good news and should be interpreted with a clinician rather than against a product label.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Zhenoluten in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Zhenoluten
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Zhenoluten — frequently asked questions
Is Zhenoluten a peptide or an extract?
An extract — a peptide complex from ovary, not a single defined molecule. That is why a certificate of analysis cannot confirm its identity the way it can for a synthetic peptide.
Is there a human trial of Zhenoluten?
Nothing is indexed under the trade name Zhenoluten. No AMH, FSH or cycle endpoint has been published for any ovary-derived peptide preparation in this family.
What should I measure if I run Zhenoluten?
Before and after, not after alone. The falsifiability section on this page names the specific markers, the direction each should move and the timescale — and says what a null result would rule out.
References & further reading
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR — Peptide Regulation of Gene Expression: A Systematic Review · Molecules 2021;26(22):7053 · PMID 34834147
- Kolchina N, Khavinson V, Linkova N, Yakimov A, Baitin D, Afanasyeva A, Petukhov M — Systematic search for structural motifs of peptide binding to double-stranded DNA · Nucleic Acids Research 2019;47(20):10553–10563 · PMID 31598715
- Alsulaimani RA, Quinn TJ (independent — not the Khavinson group) — The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis · Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
What Zhenoluten is used for
Zhenoluten appears under 2 goals in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.